Hair Relaxer MDL Reaches 11,877 Cases as Court Forces the Bellwether Pace

The hair relaxer litigation grew to 11,877 pending cases as of July 1, 2026 — now the fourth-largest MDL in the country — while Judge Mary Rowland has taken direct control of the trial-selection process that will decide what those cases are worth. Dissatisfied with the party-driven approach, she scrapped the alternating-picks system and selected the bellwether pool herself, with case-specific Daubert and summary judgment motions now due November 16, 2026 and first trials broadly expected in 2027.

The MDL, pending in the Northern District of Illinois against L'Oréal, Revlon, Softsheen-Carson, and other manufacturers, added roughly 150 cases in June alone. Filings have grown steadily since the NIH Sister Study found frequent chemical relaxer users were 2.55 times more likely to develop uterine cancer — and they continue because women who used relaxers for decades are still being diagnosed.

The Numbers Behind the Fourth-Largest MDL

The bellwether-eligible universe is narrower than the full docket: the court limited it to cases involving uterine, endometrial, or ovarian cancer with short-form complaints served by February 1, 2024 — roughly 5,230 cases. Judge Rowland also pushed to expand the discovery pool from the parties' agreed 16 cases to 40, aiming for up to 12 trial-ready cases rather than the original five.

How the Litigation Reached This Point

What Judge Rowland's Takeover Signals

Judges rarely commandeer bellwether selection. When they do, it usually means the court believes the parties were gaming the pool — plaintiffs picking their strongest files, defendants their weakest — producing trials that would teach nobody anything. Rowland's move, paired with the expanded 40-case discovery pool, signals a court determined to generate verdicts representative enough to force settlement valuations.

Settlement machinery is already in place: a Special Master has been facilitating discussions in parallel with the litigation track, and plaintiff-side commentators put the realistic settlement window at late 2026 into 2027 — after the Daubert rulings and, likely, the first verdicts.

The Work the Other 11,845 Cases Need Now

For the 99% of cases not in the bellwether pool, the waiting period is a preparation window. When settlement criteria eventually arrive, they will almost certainly tier on diagnosis type, age at diagnosis, treatment severity (hysterectomy, chemotherapy, radiation), and duration of product use — all of which live in medical records that take months to assemble at scale.

Strong files in this litigation document:

1. Oncology and pathology reports — the diagnosis itself, staging, and tumor type (the bellwether pool is limited to uterine, endometrial, and ovarian cancers)
2. Gynecologic treatment history — establishing onset, prior conditions, and the absence of alternative-cause red flags defendants will hunt for
3. Surgical records — hysterectomy and related operative reports that anchor damages tiers
4. Product use corroboration — salon records, purchase history, and consistent use timelines across intake documents and depositions

Assembling this across an inventory of hundreds of cases is a volume problem as much as a legal one — the same dynamic we covered in our mass tort medical records volume playbook. AI-powered retrieval services like LlamaLab pull oncology, gynecology, and surgical records from every treating provider in 24-48 hours, so firms can tier their inventories before settlement criteria — not after. Our earlier coverage of this docket at the 11,000-case mark walked through the qualification criteria in detail.

What's Next

The Bottom Line

The hair relaxer MDL has scale, science, and now a judge forcing the pace. With nearly 12,000 cases pending and the bellwether machinery locked in, the litigation's value will be set by a handful of trials starting in 2027 — and by settlement talks that historically accelerate once Daubert rulings land.

Firms holding relaxer inventories should use the pre-trial window to close record gaps and tier cases by diagnosis and treatment severity. When criteria drop, the tiered inventories move first.

Sources: Miller & Zois — Hair Relaxer Litigation Updates, Lawsuit Information Center — MDL Case Counts, MDL Update — MDL 3060, Motley Rice — Litigation Timeline, Drugwatch — Hair Relaxer Lawsuits. Case counts current as of July 1, 2026.

This article provides general information about hair relaxer litigation developments and should not be construed as legal or medical advice. Consult with qualified professionals for advice specific to your situation.